A report of the automated radiosynthesis of the tau positron emission tomography radiopharmaceutical, [18F]‐THK‐5351

The radiotracer, [18F]‐THK‐5351, is a highly selective and high‐binding affinity PET imaging agent for aggregates of hyper‐phosphorylated tau protein. Our report is a simplified 1‐pot, 2‐step radiosynthesis of [18F]‐THK‐5351. This report is broadly applicable for routine clinical production and mult...

Full description

Saved in:
Bibliographic Details
Published inJournal of labelled compounds & radiopharmaceuticals Vol. 60; no. 2; pp. 140 - 146
Main Authors Neelamegam, Ramesh, Yokell, Daniel L., Rice, Peter A., Furumoto, Shozo, Kudo, Yukitsuka, Okamura, Nobuyuki, El Fakhri, Georges
Format Journal Article
LanguageEnglish
French
German
Published England Wiley Subscription Services, Inc 01.02.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The radiotracer, [18F]‐THK‐5351, is a highly selective and high‐binding affinity PET imaging agent for aggregates of hyper‐phosphorylated tau protein. Our report is a simplified 1‐pot, 2‐step radiosynthesis of [18F]‐THK‐5351. This report is broadly applicable for routine clinical production and multi‐center trials on account of favorable half‐life of flourine‐18 and the use of a commercially available radiosynthesis module, the GE TRACERlab™ FXFN. First, the O‐THP protected tosyl precursor underwent nucleophilic fluorinating reaction with potassium cryptand fluoride ([18F] fluoride (K[18F]/K222)) in Dimethyl sulfoxide at 110°C for 10 minutes followed by O‐THP removal by using diluted hydrochloric acid (HCl) at same temperature. [18F]‐THK‐5351 was purified via semi‐preparative high‐performance liquid chromatography and formulated by using 10% EtOH, United States Pharmacopeia (USP) in 0.9% sodium chloride for injection, USP and an uncorrected radiochemical yield of 21 ± 3.5%, with a specific activity of 153.11 ± 25.9 GBq/μmol (4138 ± 700 mCi/μmol) at the end of synthesis (63 minutes; n = 3). This work presents the cGMP radiopharmaceutical validation of the tau positron emission tomography (PET) radiopharmaceutical [18F]‐THK‐5351 on the GE Tracerlab FX‐FN. We reported an uncorrected radiochemical yield of 21 ± 3.5%, with a pecific activity of 153.11 ± 25.9 GBq/μmol (4138 ± 700 mCi/μmol) at the end of synthesis (63 min; n = 3).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0362-4803
1099-1344
DOI:10.1002/jlcr.3482